Lv4
410 积分 2022-11-04 加入
Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
26天前
已完结
Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
26天前
已关闭
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
27天前
已完结
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
27天前
已完结
Response rates of pazopanib therapy in metastatic soft tissue sarcoma using real‑world data
1个月前
已完结
Neratinib: First Global Approval
1个月前
已完结
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
1个月前
已完结
Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells
1个月前
已完结
Photodynamic therapy for acne vulgaris: A critical review from basics to clinical practice
1个月前
已完结
Photodynamic therapy for acne vulgaris: A critical review from basics to clinical practice
1个月前
已完结
皖公网安备34019202002308
